Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
NCT00152425
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
392
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
Certolizumab Pegol (CDP870)
Sponsor
UCB Pharma